COVID-19 infection, vaccination have little effect on migraine worsening
Oct 04, 2023
An increased concern about migraine worsening was a risk factor for perceived migraine worsening.
No increase seen in CV events in elderly after BNT162b2 vaccination
Dec 10, 2021
No increase was seen in the incidence of myocardial infarction, stroke or pulmonary embolism among those aged 75 years or older in France.
Effectiveness of Ad26.COV2.S vaccine stable for six months
Mar 22, 2022
A single dose of the Johnson & Johnson vaccine was 74% and 81% effective for preventing COVID-19 infection and hospitalizations, respectively, in the U.S. before and during delta variant surge.
Pollution tied to risk for serious COVID-19 despite vaccination
Oct 07, 2022
Exposures to PM2.5 and NO2 was linked to increased risk for COVID-19-related hospitalization, with and without adjustment for vaccination.
Infections reported after single dose of monkeypox vaccine
Oct 04, 2022
Most of the cases of monkeypox occurring following single dose of the MVA-BN vaccine occur within 14 days.
Plant-based recombinant COVID-19 vaccine found to be effective
May 04, 2022
Vaccine efficacy ranged from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.
Review of booster shots for Moderna, J&J vaccines just weeks away: Fauci
Sep 20, 2021
Fauci says that data on booster shots for those vaccines are only a few weeks away from a review by the FDA.
FDA advisory panel set to meet on COVID-19 booster shots
Sep 02, 2021
The U.S. Food and Drug Administration will hold a key advisory panel meeting on COVID-19 booster shots on Sept. 17, a mere three days before the Biden administration plans to begin offering third shots...
Risk for Bell’s palsy up 42 days after first dose of CoronaVac
Aug 25, 2021
A Hong Kong study shows small increased risk after the Sinovac Biotech vaccine known as CoronoVac, but no significantly increased risk after the BNT162b2 vaccine (Fosun-BioNTech [equivalent to Pfizer-BioNTech]).
FDA tells vaccine makers to update boosters to target omicron subvariants
Jun 30, 2022
Pfizer and Moderna are expected to start producing reformulated doses this summer.